2003
DOI: 10.1023/b:glyc.0000024250.48506.bf
|View full text |Cite
|
Sign up to set email alerts
|

Sialidase and malignancy: A minireview

Abstract: Aberrant sialylation in cancer cells is thought to be a characteristic feature associated with malignant properties including invasiveness and metastatic potential. Sialidase which catalyzes the removal of sialic acid residues from glycoproteins and glycolipids, has been suggested to play important roles in many biological processes through regulation of cellular sialic acid contents. The altered expression of sialidase observed in cancer would, therefore, suggest its involvement in the malignant process. In m… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

3
99
0
1

Year Published

2005
2005
2011
2011

Publication Types

Select...
8
1
1

Relationship

0
10

Authors

Journals

citations
Cited by 138 publications
(103 citation statements)
references
References 82 publications
3
99
0
1
Order By: Relevance
“…To understand the causes and consequences of such aberrant sialylation, our studies have been focused on mammalian sialidases, which regulate cell-surface sialylation by removal of sialic acids from the nonreducing terminus of glycoproteins and glycolipids. Sialidase expression levels do indeed change in response to various cellular phenomena and especially in relation to cancer phenotype (Miyagi et al, 2004(Miyagi et al, , 2008. Four types of mammalian sialidases have been cloned to date (designated Neu1, Neu2, Neu3 and Neu4) differing in their subcellular localizations and substrate specificities (Monti et al, 2002;Miyagi and Yamaguchi, 2007).…”
Section: Introductionmentioning
confidence: 99%
“…To understand the causes and consequences of such aberrant sialylation, our studies have been focused on mammalian sialidases, which regulate cell-surface sialylation by removal of sialic acids from the nonreducing terminus of glycoproteins and glycolipids. Sialidase expression levels do indeed change in response to various cellular phenomena and especially in relation to cancer phenotype (Miyagi et al, 2004(Miyagi et al, , 2008. Four types of mammalian sialidases have been cloned to date (designated Neu1, Neu2, Neu3 and Neu4) differing in their subcellular localizations and substrate specificities (Monti et al, 2002;Miyagi and Yamaguchi, 2007).…”
Section: Introductionmentioning
confidence: 99%
“…(3,17). They also point to possible changes in the activity/ expression of enzymes involved in glycosylation processes, both glycosyltransferases and glycosidases (18,19). In general, the glycophenotype of PCa is, among other changes, associated with an increase of sialic acid in cancerous tissue compared to normal tissue and may differentiate clearly between tumor cell sublines (20,21).…”
Section: Discussionmentioning
confidence: 99%
“…2), in the NANA residue, except for the reducing end, the 2-keto position is occupied by glycoside linkages. However, it is also known that the sialidase activity also changes in certain cancers, 12) and this will supply free sialic acids to the inflamed region. In addition, Eguchi et al reported the NANA-specific release from the cell surface sialyl Lewis X by ROS treatment.…”
Section: Discussionmentioning
confidence: 99%